Inhibitory Effects of Enterolactone on Growth and Metastasis in Human Breast Cancer

REFERENCES

• Adlercreutz H and Mazur W: Phyto-oestrogens and Western diseases. Annals of Medicine 29, 95–120, 1997.
   PubMed Web of Science ®Google Scholar
• Touillaud MS, Thiebaut AC, Fournier A, Niravong M, Boutron-Ruault MC, et al.: Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. Journal of the National Cancer Institute 99, 475–486, 2007.
   PubMed Web of Science ®Google Scholar
• Adlercreutz H: Lignans and human health. Critical Reviews in Clinical Laboratory Sciences 44, 483–525, 2007.
   PubMed Web of Science ®Google Scholar
• McCann SE, Thompson LU, Nie J, Dorn J, Trevisan M, et al.: Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Research and Treatment 122, 229–235, 2010.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Hoikkala A, Leppala E, and Wahala K: Enterolignans. Journal of Chromatography: B. Analytical Technologies in the Biomedical and Life Sciences 777, 29–43, 2002.
   PubMed Web of Science ®Google Scholar
• Lampe JW, Atkinson C, and Hullar MA: Assessing exposure to lignans and their metabolites in humans. Journal of AOAC International 89, 1174–1181, 2006.
   PubMed Web of Science ®Google Scholar
• Penalvo JL, Heinonen SM, Aura AM, and Adlercreutz H: Dietary sesamin is converted to enterolactone in humans. The Journal of Nutrition 135, 1056–1062, 2005.
   PubMed Web of Science ®Google Scholar
• Bergman Jungestrom M, Thompson LU, and Dabrosin C: Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13, 1061–1067, 2007.
   PubMed Web of Science ®Google Scholar
• Saarinen NM, Abrahamsson A, and Dabrosin C: Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. International Journal of Cancer/Journal international du cancer 127, 737–745, 2010.
   PubMed Web of Science ®Google Scholar
• Chen J and Thompson, LU: Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Research and Treatment 80, 163–170, 2003.
   PubMed Web of Science ®Google Scholar
• Guglielmini P, Rubagotti A, and Boccardo F: Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Research and Treatment 132, 661–668. 2012.
   PubMed Web of Science ®Google Scholar
• Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, et al: Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. International Journal of Cancer/Journal international du cancer 135, 923–933, 2014.
   PubMed Web of Science ®Google Scholar
• Buck K, Vrieling A, Zaineddin AK, Becker S, Husing A, et al.: Serum enterolactone and prognosis of postmenopausal breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29, 3730–3738, 2011.
   PubMed Web of Science ®Google Scholar
• Chen J, Stavro PM, and Thompson LU: Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutrition and Cancer 43, 187–192, 2002.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen J, and Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. International Journal of Cancer/Journal international du cancer 116, 793–798, 2005.
   PubMed Web of Science ®Google Scholar
• Li D, Yee JA, Thompson LU, and Yan L: Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Letters 142, 91–96, 1999.
   PubMed Web of Science ®Google Scholar
• Miura D, Saarinen NM, Miura Y, Santti R, and Yagasaki K: Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats. Nutrition and Cancer 58, 49–59, 2007.
   PubMed Web of Science ®Google Scholar
• Xiong X, Wang Y, Liu C, Lu Q, Liu T, et al: Heat shock protein 90beta stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Experimental Cell Research 326, 78–89, 2014.
   PubMed Web of Science ®Google Scholar
• Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, et al: Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. The Journal of Clinical Investigation 119, 252–266, 2009.
   PubMed Web of Science ®Google Scholar
• Etienne-Manneville S: Actin and microtubules in cell motility: which one is in control? Traffic 5, 470–477, 2004.
   PubMed Web of Science ®Google Scholar
• Prasad K: Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. The International Journal of Angiology: Official Publication of the International College of Angiology 9, 220–225, 2000.
   PubMedGoogle Scholar
• Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X, et al: Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Molecular Cancer Therapeutics 6, 2581–2590, 2007.
   PubMed Web of Science ®Google Scholar
• Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I, et al: Role of thallium-201 chloride and Tc-99m methoxy-isobutyl-isonitrite (sestaMIBI) in evaluation of breast masses: correlation with the immunohistochemical characteristic parameters (Ki-67, PCNA, Bcl, and angiogenesis) in malignant lesions. Anticancer Research 17, 1639–1644, 1997.
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Orinovskii MB, Gurevich LE, Kazantseva IA, Talaeva ShZh, et al: Expression of biomolecular markers (Ki-67, PCNA, Bcl-2, BAX, BclX, VEGF) in breast tumors. Bulletin of Experimental Biology and Medicine 137, 182–185, 2004.
   PubMed Web of Science ®Google Scholar
• Wonsey DR and Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Research 65, 5181–5189, 2005.
   PubMed Web of Science ®Google Scholar
• Wierstra I and J Alves: FOXM1, a typical proliferation-associated transcription factor. Biological Chemistry 388, 1257–1274, 2007.
   PubMed Web of Science ®Google Scholar
• Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, et al: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PloS One 4, e4849, 2009.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri P and Park HJ: FoxM1: a master regulator of tumor metastasis. Cancer Research 71, 4329–4333, 2011.
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Van Bockstaele DR, and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation 36, 131–149, 2003.
   PubMed Web of Science ®Google Scholar
• McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, et al: Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Molecular Nutrition & Food Research 52, 567–580, 2008.
   PubMed Web of Science ®Google Scholar
• Hanks SK, Ryzhova L, Shin NY, and Brabek J: Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Frontiers in Bioscience: A Journal and Virtual Library 8, d982–d996, 2003.
   PubMed Web of Science ®Google Scholar
• Mitra SK, Hanson DA, and Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nature Reviews: Molecular Cell Biology 6, 56–68, 2005.
   PubMed Web of Science ®Google Scholar
• McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, et al: The role of focal-adhesion kinase in cancer: a new therapeutic opportunity. Nature Reviews: Cancer 5, 505–515, 2005.
   PubMed Web of Science ®Google Scholar
• Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, et al: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 6, 2417–2423, 2000.
   PubMed Web of Science ®Google Scholar
• Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, et al: Structural basis for the autoinhibition of focal adhesion kinase. Cell 129, 1177–1187, 2007.
   PubMed Web of Science ®Google Scholar
• Deakin NO and Turner CE: Paxillin comes of age. Journal of Cell Science 121(Pt 15), 2435–2444, 2008.
   PubMed Web of Science ®Google Scholar
• Schaller MD and Parsons JT: pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Molecular and Cellular Biology 15, 2635–2645, 1995.
   PubMed Web of Science ®Google Scholar
• Burridge K, CE Turner, and LH Romer: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. The Journal of Cell Biology 119, 893–903, 1992.
   PubMed Web of Science ®Google Scholar